Semler Scientific (NASDAQ:SMLR) Releases Earnings Results, Beats Estimates By $1.21 EPS

Semler Scientific (NASDAQ:SMLR) released its earnings results on Wednesday. The company reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $1.21, FiscalAI reports. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.The company had revenue of $7.49 million during the quarter, compared to the consensus estimate of $7.87 million.

Semler Scientific Stock Down 5.9%

Shares of NASDAQ:SMLR opened at $25.73 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.60 and a quick ratio of 0.58. The business has a 50 day simple moving average of $27.69 and a two-hundred day simple moving average of $33.39. Semler Scientific has a 1 year low of $21.84 and a 1 year high of $81.56. The firm has a market capitalization of $389.55 million, a PE ratio of 10.59 and a beta of 1.44.

Institutional Trading of Semler Scientific

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Semler Scientific by 9.5% in the 3rd quarter. Vanguard Group Inc. now owns 700,505 shares of the company’s stock worth $21,015,000 after buying an additional 61,037 shares during the period. Raymond James Financial Inc. increased its holdings in Semler Scientific by 50.5% during the 2nd quarter. Raymond James Financial Inc. now owns 81,450 shares of the company’s stock worth $3,155,000 after purchasing an additional 27,347 shares during the period. Royal Bank of Canada raised its position in Semler Scientific by 101.2% during the 1st quarter. Royal Bank of Canada now owns 43,977 shares of the company’s stock valued at $1,592,000 after purchasing an additional 22,123 shares in the last quarter. Nomura Holdings Inc. grew its position in shares of Semler Scientific by 5.8% during the 2nd quarter. Nomura Holdings Inc. now owns 37,824 shares of the company’s stock worth $1,465,000 after buying an additional 2,062 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in Semler Scientific by 13.4% in the second quarter. Ameriprise Financial Inc. now owns 28,819 shares of the company’s stock worth $1,116,000 after buying an additional 3,411 shares in the last quarter. 49.37% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SMLR shares. Benchmark lowered their price target on shares of Semler Scientific from $101.00 to $86.00 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Cantor Fitzgerald cut their price target on Semler Scientific from $61.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Semler Scientific in a report on Wednesday, October 8th. Finally, Maxim Group cut their target price on shares of Semler Scientific from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Friday, September 19th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Semler Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $74.25.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.